CVR number 41991437
Industry 21.2000 Manufacture of pharmaceutical preparations

VDC Holding ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 3.1% 3.1% 2.6%  
Credit score (0-100)  0 0 54 56 61  
Credit rating  N/A N/A BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -3.5 -3.5 -3.5  
EBITDA  0.0 0.0 -3.5 -3.5 -3.5  
EBIT  0.0 0.0 -3.5 -3.5 -3.5  
Pre-tax profit (PTP)  0.0 0.0 -4.2 -3.9 -4.4  
Net earnings  0.0 0.0 -4.2 -3.9 -4.4  
Pre-tax profit without non-rec. items  0.0 0.0 -4.2 -3.9 -4.4  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 996 992 987  
Interest-bearing liabilities  0.0 0.0 5.0 9.3 93.7  
Balance sheet total (assets)  0.0 0.0 1,004 1,005 1,085  
Net Debt  0.0 0.0 0.7 5.5 86.4  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -3.5 -3.5 -3.5  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 1,004 1,005 1,085  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% 8.0%  
Added value  0.0 0.0 -3.5 -3.5 -3.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -0.3% -0.3% -0.3%  
ROI %  0.0% 0.0% -0.3% -0.3% -0.3%  
ROE %  0.0% 0.0% -0.4% -0.4% -0.4%  

Solidity 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  0.0% 0.0% 99.2% 98.7% 91.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -21.3% -158.5% -2,467.9%  
Gearing %  0.0% 0.0% 0.5% 0.9% 9.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 30.0% 6.0% 1.7%  

Liquidity 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.0 0.0 0.5 0.4 0.1  
Current Ratio  0.0 0.0 0.5 0.4 0.1  
Cash and cash equivalent  0.0 0.0 4.2 3.8 7.3  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 -4.2 -8.2 -89.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0